Interleukin 18: Friend or foe in cancer

被引:50
|
作者
Palma, Giuseppe [1 ,5 ]
Barbieri, Antonio [1 ]
Bimonte, Sabrina [1 ]
Palla, Marco [2 ]
Zappavigna, Silvia [4 ]
Caraglia, Michele [4 ]
Ascierto, Paolo A. [2 ]
Ciliberto, Gennaro [3 ]
Arra, Claudio [1 ]
机构
[1] Ist Nazl & Cura Tumori Fdn Giovanni Pascale IRCCS, Struttura Semplice Dipartimentale Sperimentaz Ani, Milan, Italy
[2] Ist Nazl & Cura Tumori Fdn Giovanni Pascale IRCCS, UOC Oncol Med & Terapie Innovat, Milan, Italy
[3] Ist Nazl & Cura Tumori Fdn Giovanni Pascale IRCCS, Milan, Italy
[4] Univ Naples 2, Dipartimento Biochim & Biofis & Patol Gen, I-80138 Naples, Italy
[5] CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy
来源
关键词
Tumor immunology; Immune regulation; GAMMA-INDUCING FACTOR; MURINE MELANOMA-CELLS; ENDOTHELIAL GROWTH-FACTOR; HUMAN GASTRIC-CANCER; IFN-GAMMA; SIGNALING PATHWAYS; INTERFERON-GAMMA; BINDING-PROTEIN; ANTITUMOR-ACTIVITY; IMMUNE ESCAPE;
D O I
10.1016/j.bbcan.2013.09.001
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In the last few years, the field of tumor immunology has significantly expanded and its boundaries, never particularly clear, have become less distinct. Although the immune system plays an important role in controlling tumor growth, it has also become clear that tumor growth can be promoted by inflammatory immune responses. A good example that exemplifies the ambiguous role of the immune system in cancer progression is represented by interleukin 18 (IL-18) that was first identified as an interferon-gamma-inducing factor (IGIF) involved in T helper type-1 (Th1) immune response. The expression and secretion of IL-18 have been observed in various cell types from immune cells to circulating cancer cells. In this review we highlighted the multiple roles played by IL-18 in immune regulation, cancer progression and angiogenesis and the clinical potential that may result from such understanding. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:296 / 303
页数:8
相关论文
共 50 条
  • [31] Chemotherapy: Friend or foe to cancer vaccines?
    Emens, LA
    Machiels, JP
    Reilly, RT
    Jaffee, EM
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2001, 3 (01) : 77 - 84
  • [32] Hydrogen sulfide in cancer: Friend or foe?
    Wu, Dongdong
    Si, Weirong
    Wang, Mingjie
    Lv, Shuangyu
    Ji, Ailing
    Li, Yanzhang
    NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 2015, 50 : 38 - 45
  • [33] Editorial: Anesthesia and cancer: Friend or foe?
    Bezu, Lucillia
    Diaz-Cambronero, Oscar
    Kepp, Oliver
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [34] Sunitinib in breast cancer: Friend or foe
    Cardoso, Fatima
    Senkus-Konefka, Elzbieta
    BREAST, 2009, 18 (04): : 211 - 212
  • [35] Corticosteroids and Prostate Cancer: Friend or Foe?
    Geynisman, Daniel M.
    Szmulewitz, Russell Z.
    Plimack, Elizabeth R.
    EUROPEAN UROLOGY, 2015, 67 (05) : 874 - 875
  • [36] Rho GTPases in cancer: friend or foe?
    Svensmark, Julius H.
    Brakebusch, Cord
    ONCOGENE, 2019, 38 (50) : 7447 - 7456
  • [37] Sulfonylurea derivatives and cancer, friend or foe?
    Hendriks, Anne M.
    Schrijnders, Dennis
    Kleefstra, Nanne
    de Vries, Elisabeth G. E.
    Bilo, Henk J. G.
    Jalving, Mathilde
    Landman, Gijs W. D.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 861
  • [38] Ferroptosis: friend or foe in cancer immunotherapy?
    Demuynck, Robin
    Efimova, Iuliia
    Catanzaro, Elena
    Krysko, Dmitri, V
    ONCOIMMUNOLOGY, 2023, 12 (01):
  • [39] Autophagy: Is it cancer's friend or foe?
    Marx, J
    SCIENCE, 2006, 312 (5777) : 1160 - 1161
  • [40] Alternative nutrition in cancer: friend or foe?
    Holmes, S
    JOURNAL OF THE ROYAL SOCIETY FOR THE PROMOTION OF HEALTH, 2003, 123 (02): : 76 - 76